Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Jenoptik AG (ETR:JEN) wird in den nächsten drei Tagen ex-dividendienz handeln. Der Ex-Dividenden-Tag ist üblicherweise zwei Geschäftstage vor dem Record-Tag, der die Grenze für Aktionäre darstellt, um für eine Dividende zu qualifizieren. Es ist wichtig, sich des Ex-Dividenden-Tags bewusst zu sein, da jede Transaktion auf dem Aktienmarkt vor dem Record-Tag abgeschlossen werden muss. Daher sind Anleger, die am 10. Juni Aktien von Jenoptik kaufen, nicht für eine Dividende qualifiziert, wenn sie am 12. Juni ausgezahlt wird.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Der Order-Eingang von Jenoptik AG (JNPKF) erreichte fast EUR357 Millionen, was einen neuen Rekord darstellt. Die Umsatzmarge lag um 1% unter dem Vorjahreswert bei etwa EUR241 Millionen; ohne Währungseffekte wäre sie um knapp 2% gestiegen. Der EBITDA betrug etwa EUR44 Millionen, ein Plus von über 22% gegenüber dem Vorjahr. Die EBITDA-Marge verbesserte sich um rund 350 Basispunkte. Das Nettoergebnis: Der Gewinn pro Aktie erreichte EUR0,29 im Vergleich zu EUR0,16 im ersten Quartal des Vorjahres. Der Free Cash Flow lag unter dem Vorjahreswert aufgrund höherer Working-Capital-Bedarf. Der Book-to-Bill-Ratio stieg stark auf fast 1,5 an. Das Order-Backlog wuchs auf EUR719 Millionen. Die Semiconductor & Advanced Manufacturing Revenue stiegen um etwa 7% im Vergleich zum Vorjahr. Die Biophotonics Revenue sank um etwa 11% aufgrund hoher Vergleichswerte aus dem Vorjahr. Die Smart Mobility Solutions Revenue stiegen fast um 11%. Die Bruttomarge verbesserte sich deutlich gegenüber dem Vorjahr. Die EBIT-Marge erhöhte sich auf 10,7% im ersten Quartal. Der Working-Capital-Ratio war vorübergehend erhöht aufgrund der Halbleiter-Start-up-Support. Das Umsatzprognose für 2026: Erwartet wird ein Plus in der einstelligen Prozentzahl gegenüber dem Vorjahr. Die EBITDA-Marge-Prognose für 2026: Erwartet wird eine Marge zwischen 19% und 21% auf Volljahresbasis.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Aktionäre werden begeistert sein, da ihr Anteil in den letzten sieben Tagen um 32 % gestiegen ist, nachdem Jenoptik AG (ETR: JEN) ihre jüngsten ersten Quartalszahlen veröffentlicht hat. Umsätze beliefen sich auf €241 Mio., was ungefähr der Erwartung entspricht, obwohl die gesetzlichen Gewinn pro Aktie (EPS) die Erwartungen übertroffen haben und bei €0,29 landeten, ein beeindruckender 24 % über den Schätzungen. Nach dem Ergebnis haben sich die Analysten ihre Earnings-Modelle angepasst und es wäre interessant zu wissen, ob sie glauben, dass sich das Unternehmen in seiner Perspektive stark verändert hat oder wenn es nur Geschäfts wie gewohnt ist. Mit diesem Hintergrund haben wir die neuesten gesetzlichen Prognosen zusammengetragen, um zu sehen, was die Analysten für das nächste Jahr erwarten.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Jenoptik logo

Key Points

Jenoptik positions itself as a globally leading photonics OEM supplier across semiconductors, medtech/biophotonics, metrology and smart mobility, generating about €1 billion in revenue and roughly an 18% EBITDA margin last year. In 2025 group revenue fell ~6% (mainly from semiconductor inventory adjustments and weak automotive demand) but the company preserved profitability with an 18.4% EBITDA margin, improved free cash flow by ~€50m and reduced leverage to 1.6x after cost and restructuring actions. For 2026 Jenoptik guides to 1%–9% revenue growth and a 19%–21% EBITDA margin, citing stronger semiconductor and biophotonics momentum and new capacity (a ~€100m Dresden plant), while warning macro and automotive cyclicality remain key downside risks. Interested in Jenoptik AG? Here are five stocks we like better.

Jenoptik (ETR:JEN) highlighted its positioning as a photonics-focused supplier to semiconductor, medical and life science, metrology and smart mobility markets during a presentation at the digital German Select Conference, with Head of IR and Sustainability Andreas Theisen outlining 2025 performance, recent strategic actions and guidance for 2026.

Photonics focus and OEM-driven business model

Theisen described Jenoptik as “globally leading in the world of photonics,” centered primarily on optics and lasers. He said the company generates “about a billion” euros in revenue and reported “a little above 18% EBITDA margin last year.”

→ 3 Surprising S&P 500 Outperformers of 2026

Jenoptik’s model is largely OEM-based, meaning its components are typically integrated into customers’ equipment rather than sold directly to consumers. Theisen said the company usually works with customers via joint R&D projects rather than selling off-the-shelf products, and then supplies the resulting solution throughout the customer product’s life cycle.

Customer concentration is a key feature of that model. Theisen noted that “a little less than 50%” of total group sales come from Jenoptik’s top seven customers, adding that these relationships are deep and often involve shared R&D and commercial roadmaps.

Key end markets and examples of applications

→ Microsoft’s Copilot Problem Isn’t What You Think

Theisen framed photonics as a “platform technology” and said Jenoptik deploys its expertise into four core end markets: semiconductors, medtech/life science, metrology, and smart mobility.

Semiconductors: Jenoptik supplies sensors and related solutions used in lithography, which Theisen characterized as essential to modern high-performance chip manufacturing. Metrology: The company is “market leading in smartphone camera testing,” according to Theisen, with its systems used in camera module quality control. Life science/medtech: Jenoptik provides specialized lasers for ophthalmology and supports other medical applications. Smart mobility: The firm supplies traffic enforcement systems such as red-light and speed control technologies for municipalities and police.

Story Continues

Business units: semicon, biophotonics, metrology/production solutions, and smart mobility

Theisen said Jenoptik has reorganized into four business units, split between OEM-focused activities and solutions businesses.

→ With Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?

Semiconductor & Advanced Manufacturing is the largest and most profitable unit, he said. In lithography, Theisen identified ASML as the key customer and said Jenoptik’s products are “performance critical” and jointly designed with the customer. He added the company is present across ASML lithography technologies, including both DUV and EUV-related platforms. The unit also sells optical components used in semiconductor inspection and metrology tools to customers including KLA and Applied Materials.

Biophotonics includes life science and medtech OEM customers. Theisen cited dentistry as the largest application area, describing production of intraoral scanners for a large U.S. corporation. He also pointed to ophthalmology partnerships and a developing opportunity in microsurgery, including support for procedures such as artificial knee transplants. He added that manufacturing allocated to this unit also produces a portfolio used in defense, stating defense contributes roughly 5%–6% of total group revenue, or “something like around…EUR 50 million.”

Metrology & Production Solutions is part of the solutions business, supplying full machines, including for smartphone camera testing, and other metrology devices. Theisen said about 50% of this unit’s revenue is tied to automotive end markets, which he noted are under pressure. He cited tactile measurement technology for combustion engines as an example of an area facing headwinds. The unit is also targeting longer-term growth tied to AR/VR, which Theisen said remains “early days” but could be meaningful if devices reach mass adoption.

Smart Mobility Solutions provides traffic surveillance systems, including an operating model where Jenoptik runs systems under service contracts. Theisen said recurring revenue represents about 40% of this business. He described strong positions in Germany and the U.K., and said the company is pushing into the U.S. after building selling and service infrastructure there.

2025 performance and strategic actions

Theisen said 2025 was marked by cost containment and cost control amid “somewhat lower demand than the year before.” He reported group revenue declined 6% year over year, driven primarily by inventory adjustments at the company’s main semiconductor customer early in the year and weak automotive demand. He also said the Semiconductor & Advanced Manufacturing unit saw an 11%–12% revenue decline.

Despite the revenue pressure, Theisen said Jenoptik maintained profitability, reporting an 18.4% EBITDA margin that included “EUR high single-digit million” in one-time restructuring costs. He also pointed to free cash flow improvement of about EUR 50 million and said leverage declined to 1.6x, which he described as a comfortable financial position.

Strategically, Theisen said the company has spent the last five years reshaping its portfolio through acquisitions and divestments to sharpen its focus on photonics, but now aims to grow primarily organically. He also highlighted an internal reorganization completed in 2025 to simplify structures, increase managerial accountability, speed decision-making, and improve reporting transparency for investors.

On capacity, Theisen said Jenoptik has invested heavily to support future semiconductor growth, including opening a new factory in Dresden. He described the roughly EUR 100 million facility as operational but not fully utilized yet, providing a foundation for future demand.

2026 guidance: semiconductor momentum, macro uncertainties, and margin uplift

Looking ahead, Theisen said the company is seeing demand in semiconductors that is “significantly higher than it was last year” at the start of 2026, and also cited positive momentum in biophotonics. Against that backdrop, he reiterated guidance for single-digit revenue growth, defined as 1% to 9%, and EBITDA margin of 19% to 21%.

He also pointed to increased uncertainty tied to the Iran conflict, oil price increases, and potential GDP impacts, saying the year was still early and would need to be monitored as it develops.

During Q&A, Theisen said the main swing factors behind where results land within the revenue-growth range are semiconductor and automotive trends. In semiconductors, he said the pace of the cycle and the mix of demand across technology platforms matter: Jenoptik has two platforms—classical optics and micro-optics—and he noted capacity is more available in micro-optics, potentially allowing faster conversion of demand into sales. For automotive, he said the company has not assumed a sudden return to growth, but also has not assumed an incremental decline in 2026.

On partnerships and M&A, Theisen said major transactions are largely behind the company. He added that expanding key accounts in semiconductor lithography is difficult given market structure, while life science is an area where the company “has to expand” its key account base, acknowledging the long qualification and approval cycles typical of medical devices.

About Jenoptik (ETR:JEN)

Jenoptik AG provides advanced photonic solutions and smart mobility solutions in Germany and internationally. The company provides imaging solutions and cameras, including microscope and thermographic camera, imaging modules, polymer-based camera modules, and miniaturized digital microscope subsystem; and laser and laser technology, such as laser ablation, scoring, cutting, and rangefinder, as well as laser OEM solutions comprising diode laser and disk laser technology, diode pumped disk lasers, laser systems, and LK heat sink.

The article "Jenoptik Pitches Photonics Strategy at German Select Conference, Guides 2026 Growth and Margin Lift" was originally published by MarketBeat.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

While Jenoptik AG (ETR:JEN) might not have the largest market cap around , it saw a significant share price rise of 50% in the past couple of months on the XTRA. The company is now trading at yearly-high levels following the recent surge in its share price. As a mid-cap stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock. However, could the stock still be trading at a relatively cheap price? Today we will analyse the most recent data on Jenoptik’s outlook and valuation to see if the opportunity still exists.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Is Jenoptik Still Cheap?

Great news for investors – Jenoptik is still trading at a fairly cheap price. According to our valuation, the intrinsic value for the stock is €46.32, but it is currently trading at €31.12 on the share market, meaning that there is still an opportunity to buy now. However, given that Jenoptik’s share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility.

See our latest analysis for Jenoptik

What does the future of Jenoptik look like?XTRA:JEN Earnings and Revenue Growth April 14th 2026

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. With profit expected to grow by 88% over the next couple of years, the future seems bright for Jenoptik. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

What This Means For You

Are you a shareholder? Since JEN is currently undervalued, it may be a great time to accumulate more of your holdings in the stock. With an optimistic outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as financial health to consider, which could explain the current undervaluation.

Are you a potential investor? If you’ve been keeping an eye on JEN for a while, now might be the time to enter the stock. Its buoyant future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy JEN. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed buy.

Story Continues

Diving deeper into the forecasts for Jenoptik mentioned earlier will help you understand how analysts view the stock going forward. At Simply Wall St, we have the analysts estimates which you can view by clicking here.

If you are no longer interested in Jenoptik, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

This article first appeared on GuruFocus.

Release Date: March 25, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Jenoptik AG (JNPKF) implemented a new organizational structure, increasing accountability and transparency. The company successfully brought its new micro-optics facility in Dresden online, positioning for future growth. Strong performance in the biophotonics business, with revenue up by 10%, driven by defense and med tech sectors. Smart mobility solutions business saw a revenue increase of almost 9%, particularly in the US market. Despite a challenging environment, Jenoptik AG (JNPKF) improved its operating cash flow and reduced debt significantly.

Negative Points

Overall revenue in 2025 declined by approximately 6% year on year, impacted by weaker order intake trends. The semiconductor business faced a 12% revenue drop due to softer demand in the lithography sector. Order intake for the semiconductor and advanced manufacturing unit was down by around 11% year on year. The metrology and production solutions business experienced a decline in orders due to ongoing weakness in the automotive market. EBITDA margin contracted by 150 basis points year on year, influenced by lower fixed cost absorption and product mix effects.

Q & A Highlights

Warning! GuruFocus has detected 4 Warning Sign with JNPKF. Is JNPKF fairly valued? Test your thesis with our free DCF calculator.

Q: In Q4, Jenoptik's EBITDA margin in the semi activities was around 30%. Is this an indication of a new level of profitability we can expect going forward? A: Dr. Priska Harrannek, Head of Investor Relations, explained that while the Q4 margin was strong due to a better product mix and cost reductions, it also included one-time effects. Moving forward, they expect good margins but anticipate cost inflation and additional resources needed for ramp-up, which may not lead to a different margin environment in 2026.

Q: Can you provide more details on increasing your share of wallet in the inspection space and the sales split between lithography and inspection activities? A: Dr. Priska Harrannek highlighted that the inspection business has seen growth in both order intake and revenue, contrasting with the lithography business. Strategically, they aim to build a second large pillar outside of lithography, focusing on gaining a larger share of the wallet from customers.

Q: Regarding Prodomax, the order intake was low in 2025, and the backlog is almost done. What are the expectations for 2026, and what measures are being implemented to mitigate this? A: Dr. Priska Harrannek noted that Prodomax experienced an order cancellation in Q4 2025, reflecting a volatile demand situation in the North American OEM space. Prodomax is asset-light with flexible costs, and management is monitoring the situation closely. They believe the demand will return given Prodomax's strong market position.

Story Continues

Q: Do you expect a similar sequential margin development in 2026 as in 2025, considering the subdued Q1 growth rate? A: Dr. Priska Harrannek expects Q1 2026 revenues to be below Q1 2025 due to current demand patterns and internal capacities. However, they anticipate an acceleration in demand and revenue in subsequent quarters, with a stronger H2 compared to H1.

Q: Can you provide more color on capacity availability and the order-to-revenue conversion cycle in the semis business? A: Dr. Priska Harrannek explained that classical optical components have longer lead times, while micro-optics have shorter cycles. They have ample capacity in Dresden for future growth and have added moderate capacity in Germany. Operational execution will be key to balancing demand and capacity.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

View Comments